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Background: AKI is common among hospital in-patients and places a huge financial burden on the UK National
Health Service, causing increased length of hospital stay and use of critical care services, with increased requirement
for complex interventions including dialysis. This may account for up to 0.6% of the total Health Service budget. To
investigate the incidence and consequences of AKI, all unselected emergency admissions to a large acute UK single
centre University Teaching Hospital over two separate 7 day periods were reviewed.
Methods: A retrospective audit of 745 case records was undertaken (54.6% male) including laboratory data
post-discharge or death, with classification of AKI by RIFLE, AKIN and AKIB criteria. Participants were included
whether admitted via their general practitioners, the emergency department, or as tertiary specialty transfers.
Outcome measures were presence or absence of AKI recorded using each of the three AKI criteria, length of
hospital stay (LOS), admission to, and LOS in critical care, and mortality. The most severe grade of AKI only,
at any time during the admission, was recorded to prevent double counting. Renal outcome was determined
by requirement for renal replacement therapy (RRT), and whether those receiving RRT remained dialysis
dependent or not.
Results: AKI incidence was 25.4% overall. With approximately one third present on admission and two thirds
developing post admission. The AKI group had LOS almost three times higher than the non AKI group (10 vs
4 days). Requirement for critical care beds was 8.1% in the AKI group compared to 1.7% in non AKI group.
Overall mortality was 5.5%, with the AKI group at 11.4% versus 3.3% in the non AKI group.
Conclusions: AKI in acute unselected hospital admissions is more common than existing literature suggests,
affecting 25% of unselected admissions. In many this is relatively mild and may resolve spontaneously, but is
associated with increased LOS, likelihood of admission to critical care, and risk of death. If targeted effective
interventions can be developed it seems likely that substantial clinical benefits for the patient, as well as
financial and structural benefits for the healthcare organisation may accrue.
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In 2009 The National Confidential Enquiry into Patient
Outcomes and Death (NCEPOD) report - “Adding Insult
to Injury” - published a review of the care of patients
who died in UK hospitals with a primary diagnosis of
acute kidney injury [1]. The principal findings suggested
that whilst organisational issues, such as delays in access
to diagnostics and specialist care, contribute to the prob-
lems in managing Acute Kidney Injury (AKI), a more
significant problem is failure of clinicians to recognise
AKI at an early stage. This leads to delays in appropriate
management and referral to specialist renal services, es-
pecially in patients who developed AKI post admission.
Acute kidney injury is a common but complex condi-
tion that occurs on all acute hospital sites and in all
areas of the hospital, but which generally does not result
in a requirement for dialysis treatment. It is accepted
that AKI is associated with high individual morbidity
and mortality, and places a huge financial burden on the
UK National Health Service (NHS) in terms of increased
length of hospital stay, plus increased requirement for
complex interventions and critical care services. It is esti-
mated that total yearly costs of AKI (including acute hos-
pital admissions, critical care and RRT) was 0.4 - 0.6% of
the total UK NHS budget (range between £434million and
£620million in 2009–2010) [2-4] Added to this is the
long-term cost of subsequent chronic kidney disease,
including renal replacement therapy if end stage renal
failure (ESRF) is reached [5].
No definitive studies have been undertaken within the
UK to determine the precise prevalence of all stages of
AKI. In the US the prevalence within hospitalised pa-
tients has been shown in the past to be 5-7% [6,7]. How-
ever these studies looked at ARF (Acute Renal Failure)
rather than AKI as they pre-dated the 3 AKI classifica-
tion systems we used. A more recent study from the US
published this year, has shown AKI incidence of between
7.0-18.3% depending on which classification system was





























Acute Dialysis Quality Initiative “RIFLE” criteria (risk, injury, failure, loss, End Stage Re
(Bonventre), MDRD eGFR (Modification of Diet in Renal Disease estimated GlomerulaUnits (ICU) is considerably higher, with rates of AKI of
up to 85% and between 5-15% requiring RRT [9,10].
Data from the UK Intensive Care National Audit Re-
search Centre (ICNARC) suggests that AKI accounts
for nearly 10 percent of all ICU bed days [11]. AKI re-
quiring RRT has been reported to account for 4.9% of
all admissions to Intensive Care [12]. Comparison of
these studies is made difficult by the varying defini-
tions of AKI used in the literature. However, since
2004 more precise terminology and generally accepted
definitions of AKI [13,14] have enabled healthcare pro-
fessionals to define the disease more consistently, with
a spectrum of injury severity ranging from milder
self-limiting forms to more advanced injury possibly
requiring RRT.
Despite these improvements in terminology, at the
time of this study three definitions of AKI were in use
(Table 1);
1) The Acute Dialysis Quality Initiative “RIFLE” criteria
[15] (risk, injury, failure, loss, ESRD), and.
2) “AKIN” (Acute Kidney Injury Network) criteria [16].
3) “AKI (Bonventre)” criteria, referred to in this
manuscript as AKIB, which does not reference urine
output.
For this reason data was collected which allowed
analysis using all three definitions. This was to ensure
the data would remain relevant for comparison in fu-
ture studies when a clear definition is adopted, and
also to allow comparison between the three different
systems. The AKI guidelines published in 2012 by the
international guideline group, Kidney Disease: Improv-
ing Global Outcomes (KDIGO) has now proposed a
combination of RIFLE and AKIN, and this definition
seems likely to be globally accepted [17,18]. Hopefully
this will enable consistency in future comparisons of
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kidney function which may result in a failure to maintain
fluid, electrolyte and acid–base homoeostasis. However
there is now increasing recognition that even a relatively
small rise in serum creatinine in a variety of clinical
settings is associated with worse outcomes and AKI has
been demonstrated to be an independent risk factor for
mortality [19-21]. Increasing severity of AKI is associ-
ated with a further increased risk of death, and this is
independent of co-morbidity [21-23]. If early AKI can be
rapidly identified and appropriate management promptly
instituted it may be possible to reduce the associated
increased mortality, although this is not certain.
Aims
We wished to study the incidence and the consequences
of acute kidney injury in all unselected emergency ad-
missions to the large acute UK hospital centre in which
our regional renal service is based.
Methods
All emergency admissions to Manchester Royal Infirmary,
over two separate seven day periods, were included whether
admitted via their general practitioners, the emergency
department, or as tertiary specialty transfers. This included
all acute medical and surgical admissions via general
practice or the emergency department, as well acute
admissions via tertiary referrals to Cardiology, Haema-
tology, Transplant medicine, Vascular and Cardiothor-
acic surgery and Ophthalmology. Maternity admissions
were excluded because of the large numbers and low
likelihood of AKI, as were patients whose admission
was for less than 24 hours. Data from two separate
weeks (September and February) were utilised because
data collection over a continuous two week period was
not possible for staffing reasons. Any readmissions
were counted as a separate admission on each occasion
whether readmitted in the 7 day study period or admit-
ted in both weeks studied. A review of all case records
of the 745 emergency admissions to the trust during
these two separate week periods was conducted by RC,
JR and PL. A small team was used for the case note re-
view, all of whom have a clinical medical background
in Nephrology and/or Intensive Care medicine. This
allowed standardisation of methods. RC acted as the
final adjudicator in cases of disagreement.
Using hospital biochemistry database and paper records,
each set of notes was reviewed for evidence of AKI either
on admission or at any time during the admission. Previous
hospital biochemistry records were checked and the lowest
of any prior serum creatinine or Modification of Diet in
Renal Disease Glomerular Filtration Rate (MDRD eGFR)
from the past 6 months was recorded as the ‘baseline’ renal
function. Exact urine output volume measurements (ml/kg)were not possible to collect due to paucity and/or inaccur-
acy of data. If the admission serum creatinine or estimated
MDRD eGFR were better than the result in the previous
6 month period then the better result was assumed to be
the patient’s baseline renal function. If there was no re-
corded result within the past 6 months then the patient
was assumed to have a ‘normal’ eGFR (75 mls/min) or
serum creatinine of >60 umol/l if female or >80 umol/l if
male, unless there was a definite history of renal impair-
ment or chronic kidney disease (CKD). Each patient’s blood
results throughout their entire hospital episode were
reviewed. A computerised data collection form was utilised
to allow data obtained from the hospital case records to be
entered in a format that could be converted to an Excel
spreadsheet for analysis.
The following information was obtained for each
admission:
 Basic demographics including ethnicity
 Initial route of admission, and admitting specialty
 Weekday of admission was also noted as previous
studies have suggested poorer outcomes for
weekend admissions [24].
 Serum creatinine level and MDRD eGFR at
admission.
 Appropriateness of repeat testing of blood urea
nitrogen, creatinine and electrolytes was adjudicated.
All patients with an MDRD eGFR < 60 mls/min
were considered to require repeat testing (unless no
change from a documented baseline creatinine or
eGFR in the past 6 months). If patients had a single
blood test only but eGFR > 60 mls/min then a
clinical assessment was made by RC as to whether
repeat testing was indicated [1].
 Presence or absence of AKI was recorded using each
of the three AKI criteria - RIFLE, AKIN and AKIB
to allow comparison between the three different
systems, and also to ensure that the data remained
relevant for comparison to future studies if a specific
one of the 3 criteria was universally adopted. The
most severe grade of AKI only, at any time during
the admission, was recorded in order to prevent
double counting. The baseline renal function was
taken as either the lowest of their admission or
previous 6 month serum creatinine or eGFR if a
baseline result was available. If there was no baseline
then a ‘normal’ eGFR of >75 mls/min was assumed.
 Time of development of AKI – either present on
admission (pre-admission), or developing during the
hospital stay (post admission). If the creatinine or
eGFR were abnormal on admission and no baseline
was available (and hence assumed to be a pre
admission AKI) then for the purposes of this study
and scoring of the severity then the time in rise of
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7 days when using RIFLE and 48 hours using AKIN.
 Presence of oliguria (defined as urine output < 400 mls/
day) and anuria was recorded.
 Documentation of urinalysis being performed. The
complete nursing, medical notes and observations
charts were reviewed and if there was no
documentation of the result then it was assumed
not to have been performed.
 Ultrasound scans of kidneys within 24 hours of
development of AKI.
 Presence or absence of diabetes mellitus,
hypertension, sepsis, known CKD and
administration of contrast, all types of diuretics,
Angiotensin converting enzyme inhibitors (ACEi)
or Angiotensin receptor blockers (ARBs) and
Non-steroidal anti-inflammatories (NSAIDS) as
well as age > 65 and age > 80 was collected. Sepsis
was defined as presence of at least two of the
following indicators - white cell count <4×109/L
or >12×109/L, C reactive protein (CRP) >50 mg/L
and pyrexia (defined as temperature >38.0 degrees
centigrade).
 Outcome. We recorded length of hospital stay,
admission to, and length of stay in, critical care bed,
and critical care and hospital mortality. The renal
outcome was determined by the requirement for
renal replacement, and whether those receiving RRT
remained dialysis dependant or not.
The governance framework regarding the conduct and
publication of audit projects in our centre is that all such
projects are registered in the audit register of the trust/
centre. Therefore ethical committee (national or regional)
approval was not required and so not sought for this study.
As it was an anonymous audit and case review of notes and
biochemistry results written informed consent was not
required for the same reason.
Statistical analysis
Summary descriptive statistics were used to explore the
demographics and admission characteristics of the sam-
ple. Relationships between risk factors and development
of an AKI were explored via linear and stepwise multiple
logistic regression. The continuous outcome, hospital
length of stay was expressed by medians and compared
between AKI groups with a Mann–Whitney test, whilst
the Kruskal-Wallis test was used to assess the correl-
ation between severity of injury and length of stay.
Odds ratios were used to compare dichotomised the
outcomes, admission to critical care and hospital mor-
tality for AKI severity. All statistical analysis was con-
ducted in R v2.15.2 with libraries gmodels, car, MASS,
Epi, Hmisc, and epitools [25-30].Results
Demographics
The total population comprised 745 patients, 54.6%
male, with 385 in the initial week, and 360 in the second
week. 6 patients whose admission was less than 24 hours
were not included, and no patient was admitted more
than once. There were no statistical differences between
the weeks in any demographic characteristics.
The ethnic mix of the admissions reflected the population
of a large UK inner city hospital. 78.9% were documented
as White, 6.7% Black, 12.6% Asian, 1.1% Chinese, 0.4%
Mixed race and 0.3% Hispanic.
86.2% (N = 642) of admissions to the hospital were via
the emergency department, whilst the initial route of ad-
mission for the remaining patients was 7.4% Medical
Admissions Unit, 1.1% Coronary Care Unit, 1.5% Surgi-
cal Assessment Unit and 3.9% other (via outpatient
clinic or inter hospital transfer).
The distribution of the admitting specialty was 63.0%
general medicine, 27.1% general surgery (includes ur-
ology/orthopaedics), 3.1% other/tertiary medical special-
ties (including haematology and renal) and 6.8% other/
tertiary surgical specialties (renal transplant, cardiothor-
acic surgery, vascular surgery).
The admissions were relatively equally split across the
days of the week (range 11.4% - 17.2%), although there
were slightly higher admissions towards the end of the
week, with fewer on Sunday and Monday.
Incidence and investigation of AKI
95.7% of the 745 patients admitted had their serum creatin-
ine and estimated Glomerular Filtration Rate (MDRD
eGFR) checked on admission. 71.7% had at least two serum
creatinine results, but a further 5.9% who were considered
by the clinicians reviewing the patients notes to have re-
quired a repeat blood test, did not.
The baseline serum creatinine and eGFR were imme-
diately available in 342 (45.9%) of the 745 total popula-
tion and 333 (45.7%) of the group when the 17 dialysis
patients were excluded. In these patients the prior blood
result would have been available to the admitting clin-
ician when reviewing the patient’s admission bloods at
time of initial presentation.
7.0% of the total patients admitted were known to the
renal service. 17 (2.3%) admissions were maintenance
dialysis patients (either haemodialysis or peritoneal dia-
lysis) and these were excluded from the analysis since
they had no effective renal function. 22 (2.9%) of the
total admissions were known to have pre-existing CKD
4 or 5, and were under renal follow-up but were in-
cluded in the study since such patients may still present
with, or develop AKI.
Of 728 patients included in the analysis, 185 (25.4%) were
judged to have AKI at some time during their admission,
Table 3 Analysis of risk factors for Acute Kidney Injury
using multivariate logistical regression (full model)
Odds ratio C.I. lower C.I. upper P-value
Known CKD 4.020 2.414 6.693 <0.001
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of AKI is exclusive, so once a patient was allocated to a
higher stage, they were excluded from all lower ones. The
grade of severity of their AKI, and the differences using the
three separate scoring systems are also shown in Table 2.
RIFLE and AKIN both give a similar incidence at the more
severe end of the spectrum with RIFLE-F (2.7%) and AKIN
stage 3 (2.9%) incidence, and the same total incidence,
23.6%. AKIB gives a lower overall incidence at 21.4% and
the split across the 3 stages differs from the other two scor-
ing systems.
Seven patients (0.9% of total population) required
acute renal replacement therapy (RRT). This equates to
approximately one third of the stage 3 AKI groups,
(30.0% of RIFLE-F and 33.3% of AKIN stage 3 and 16.7%
of AKIB stage 3). 2.3% of the admitted patients were on
chronic RRT and so altogether more than 3% of the ad-
mitted patients needed dialysis.
Of all patients developing AKI, 106 had AKI present
on admission (pre-admission AKI) and 79 patients had
AKI which developed during their hospital stay.
Only 103 patients, 14.1% of the study population
(excluding the 17 ESRF patients) underwent urinalysis,
despite the NCEPOD recommendation that this is advis-
able for all emergency admissions.
Assessment of compliance with the UK Renal Associa-
tion’s guideline that all AKI stage 3 patients should have
a renal ultrasound within 24 hours of their diagnosis
was difficult. 106 (14.2%) of the total admissions under-
went renal ultrasonography, but the majority of these ap-
peared to be as part of other investigations (such as for
abdominal pain) rather than specifically requested due to
renal impairment. Of the stage 3 AKI group RIFLE 9(45%),
AKIN 10(47.6%), AKIB 12(40%) had an ultrasound of their
renal tract during the hospital stay.
Risk factors
Each patient was assessed for multiple potential risk factors
associated with AKI. On univariate analysis the presence of
diabetes mellitus, hypertension, known CKD, sepsis, di-




Risk 14.3% (104) 1 16.1% (117) 1 9.1% (66)
Injury 6.6% (48) 2 4.7% (34) 2 8.2% (60)
Failure 2.8% (20) 3 2.9% (21) 3 4.1% (30)
Total 23.6% (172) Total 23.6% (172) Total 21.4% (156)
Acute Dialysis Quality Initiative “RIFLE” criteria (risk, injury, failure, loss, End
Stage Renal Disease), “AKIN” (Acute Kidney Injury Network), “AKIB” Acute
Kidney Injury (Bonventre), MDRD eGFR (Modification of Diet in Renal Disease
estimated Glomerular Filtration Rate.with an increased odds ratio for development of AKI,
with p-values all less than 0.05. For hypertension, known
CKD, sepsis, diuretic use and age > 65 the p values were
all <0.0001. Only NSAID usage did not show increased
odds of developing AKI.
In the multivariate logistic regression fewer predictors
remained significant in the full model once adjusted for
the others, but known CKD, sepsis and diuretic usage
were all significant (Table 3). These were all identified as
important, alongside age over 65 by stepwise regression.
When age is used in the model as a continuous pre-
dictor then similar results are found.
As the total population was a combination of two sep-
arate week’s admissions data, week was included in the
multivariate analysis as a predictor. It was found not to
be important demonstrating that there were no intrinsic
differences between our two sample weeks.
Outcomes
The length of hospital stay (LOS) tended to be greater in
patients with AKI (see Figure 1). The median LOS in the
AKI group was 10.0 days versus 4.0 days in the patients
without AKI which was found to be statistically signifi-
cant (p < 0.0001) via a Mann–Whitney test. There was
no significant difference in LOS between those patients
who were admitted with AKI (median = 8.0 days), and
those who developed AKI after admission (median =
11.0 days) (Mann–Whitney, p = 0.05, see Figure 2).
The severity of the injury correlates with length of
hospital stay, use of critical care beds and risk of death.
These findings hold true whichever of the three scoring
systems is used to define AKI. Figure 3 illustrates LOS
under the RIFLE criteria, which clearly shows increasing
length of stay with degree of injury (Kruskal-Wallis
p < 0.0001, spearmans correlation = 0.37).NSAID 1.009 0.486 2.097 0.980
Contrast 0.937 0.562 1.565 0.804
ACEi 1.195 0.746 1.914 0.458
Diuretic 1.872 1.173 2.986 0.008
Diabetic 1.025 0.638 1.647 0.917
Sepsis 7.239 4.589 11.418 <0.001
Hypertension 1.438 0.904 2.288 0.125
Age 1.020 1.008 1.032 0.001
Week 0.770 0.511 1.161 0.212
Chronic Kidney Disease (CKD) as Modification of Diet in Renal Disease
estimated Glomerular Filtration Rate (MDRD eGFR < 60 mls/min, Non-steroidal
anti-inflammatory drugs (NSAID), Angiotensin converting enzyme inhibitors
(ACEi), Confidence interval (C.I).
Figure 1 Difference in hospital length of stay in patients with
and without an Acute Kidney Injury (AKI) episode (using AKI as
identified by any of the 3 scoring systems).
Figure 3 Hospital length of stay increases with severity of
Acute Kidney Injury (using the RIFLE definitions).
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mission during the hospital stay. Of those patients with
AKI, 8.1% were admitted to critical care, compared to
only 1.7% of those without AKI. The mortality of the 26
patients admitted to critical care was considerably higher
(23.1%) than the overall hospital mortality, which for the
total emergency admissions population was 5.4%. Two of
these were ESRF dialysis patients. Of the critical care
survivors, 10.5% (2 patients) remained dialysis dependent.
Patients who developed AKI in hospital were no more
likely to require admission to critical care (9.0%) than those
developing AKI pre admission (7.5%), however this was not
significant (odds 1.2, p = 0.74).Figure 2 Differences in hospital length of stay depending on
timing of episode of Acute Kidney Injury.In each scoring system ‘risk’ or stage 1 AKI does not
appear to increase the likelihood of a critical care admis-
sion. However, the proportion admitted to Critical Care
almost doubles between ‘injury’ and ‘failure’ (RIFLE cri-
teria) and stages 2 and 3 (using AKIN criteria) although
the numbers involved are small with wide binomial con-
fidence intervals (see Table 4). Approximately 20% of the
patients with AKI require critical care support, although
not all needed or received renal replacement therapy.
The hospital mortality for the AKI group was 11.4% (7.2
to 16.9) compared to only 3.3% (2.0 to 5.2) of the admis-
sions who did not have AKI (see Table 5). The odds of
death in the AKI group compared to those without AKI
was 3.7, which was highly significant (p < 0.0001), (95% C.I.
odds 1.94-7.30). The hospital mortality is similar for pre
admission AKI (11.3%), or post admission AKI (11.4%).
Whilst there is noticeable overlap, there is a definite
increase in mortality with increasing severity of AKI.
Patients with stage 1 AKI (Rifle risk) have an odds ratio of
death of 2.0 (0.7 to 4.6, midp.exact p = 0.158), stage 2
(RIFLE-I equivalent) an odds ratio of 4.6, (1.7 to 11.2,
p = 0.004) and increasing to 9.0 (2.7 to 26.3, p = 0.001) for
stage 3 (RIFLE-F).
Sub-analysis of patients with known prior information of
renal function
339 patients are included in the sub-analysis, 129 (38.1%)
were judged to have AKI at some time during their admis-
sion, using one of the three different criteria (Table 6). As
in the full cohort RIFLE and AKIN both give a similar
incidence at the more severe end of the spectrum with
RIFLE-F (4.1%) and AKIN stage 3 (5.0%) incidence, and
similar total incidence, 35.1% and 35.4% respectively. AKIB
Table 4 Critical care usage increase with severity of AKI using three scoring systems with patient numbers (percentage
of individuals in each category) (Binomial 95% confidence intervals)
RIFLE AKIN AKIB
Stage Patients admitted to critical care Stage Patients admitted to critical care Stage Patients admitted to critical care
No AKI 12 (2.2%) No AKI 10 (1.8%) No AKI 12 (2.1%)
(1.1 to 3.7) (0.9 to 3.3) (1.1 to 3.6)
Risk 3 (2.9%) 1 5 (4.3%) 1 1 (1.5%)
(0.6 to 8.2) (1.4 to 9.7) (0.0 to 8.2)
Injury 5 (10.4%) 2 4 (11.8%) 2 7 (11.7%)
(3.5 to 22.7) (3.3 to 27.5) (4.8 to 22.6)
Failure 4 (20.0%) 3 5 (23.8%) 3 4 (13.3%)
(5.7 to 43.7) (8.2 to 47.2) (3.8 to 30.7)
Acute Dialysis Quality Initiative “RIFLE” criteria (risk, injury, failure, loss, End Stage Renal Disease), “AKIN” (Acute Kidney Injury Network), “AKIB” Acute Kidney Injury
(Bonventre), MDRD eGFR (Modification of Diet in Renal Disease estimated Glomerular Filtration Rate.
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seen across the 3 stages differs from the other two scoring
systems.
Six patients (1.8% of sub-analysis) required renal re-
placement therapy (RRT). This equates to approximately
one third of the stage 3 AKI groups, (35.7% of RIFLE-F
and 35.3% of AKIN stage 3 and 22.7% of AKIB stage 3).
Of all patients with known baseline renal function
developing AKI, 76 had AKI present on admission
(pre-admission AKI) and 53 patients had AKI which
developed during their hospital stay.
Sub group risk factors
As with the total cohort, on univariate analysis the presence
of diabetes mellitus, hypertension, known CKD, sepsis,
diuretics and age > 65 were all associated with an increased
odds ratio for development of AKI, with p-values all less
than 0.05. For known CKD, sepsis and diuretic use the
p values were all <0.0001 in the sub group.
In the multivariate logistic regression fewer predictors
remained significant once adjusted for the others, but
known CKD, sepsis and diuretic use were all significant.Table 5 Hospital mortality increases with severity of AKI usin
(percentage of individuals in each category) (Binomial 95% C
RIFLE AKIN
Stage Hospital mortality Stage H
No AKI 20 (3.6%) No AKI
(2.2 to 5.5)
Risk 7 (6.8%) 1
(2.8 to 13.5)
Injury 7 (14.6%) 2
(6.1 to 27.8)
Failure 5 (25.0%) 3
(8.7 to 49.1)
Acute Dialysis Quality Initiative “RIFLE” criteria (risk, injury, failure, loss, End Stage Re
(Bonventre), MDRD eGFR (Modification of Diet in Renal Disease estimated GlomerulaThese are also identified as most important by stepwise
regression. When age is used in the model as a continuous
predictor then the same results are found.
As the total population was a combination of two separate
week’s admissions data, week was included in the multivari-
ate analysis as a predictor. It was found not to be important
demonstrating that there were no intrinsic differences
between our two sample weeks.
Sub group outcomes
As with the total cohort, in the sub group the length of
hospital stay (LOS) tended to be greater in patients with
AKI. The median LOS in the AKI group was 9.0 days versus
5.0 days in the patients without AKI which was found to be
statistically significant (p < 0.0001) via a Mann–Whitney test.
There was also significant difference in LOS between those
patients who were admitted with AKI (median = 8.0 days),
and those who developed AKI after admission (median =
14.0 days) (Mann–Whitney, p = 0.005).
The severity of the injury correlates with length of hospital
stay (see Figure 3), use of critical care beds and risk of death.
These findings hold true whichever of the three scoringg three scoring systems with patient numbers
onfidence Intervals)
AKIB
ospital mortality Stage Hospital mortality
19 (3.4%) No AKI 19 (3.3%)
(2.1 to 5.3) (2.0 to 5.1)
12 (10.3%) 1 5 (7.6%)
(5.5 to 17.4) (2.5 to 16.8)
5 (14.7%) 2 10 (16.9%)
(5.0 to 31.1) (8.4 to 29.0)
3 (14.3%) 3 5 (16.7%)
(3.0 to 36.3) (5.6 to 34.7)
nal Disease), “AKIN” (Acute Kidney Injury Network), “AKIB” Acute Kidney Injury
r Filtration Rate.
Table 6 Incidence of AKI (in sub group of patients with




Risk 21.5% (73) 1 23.9% (81) 1 14.5% (49)
Injury 9.4% (32) 2 6.5% (22) 2 11.5% (39)
Failure 4.1% (14) 3 5.0% (17) 3 6.5% (22)
Total 35.1% (119) Total 35.4% (120) Total 32.4% (110)
Acute Dialysis Quality Initiative “RIFLE” criteria (risk, injury, failure, loss, End
Stage Renal Disease), “AKIN” (Acute Kidney Injury Network), “AKIB” Acute
Kidney Injury (Bonventre), MDRD eGFR (Modification of Diet in Renal Disease
estimated Glomerular Filtration Rate.
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teria, we see increasing length of stay with degree of injury
(Kruskal-Wallis p < 0.0001, spearmans correlation = 0.42).
3.5% (12 patients) of the subgroup had a critical care ad-
mission during the hospital stay. Of those patients with AKI,
6.2% were admitted to critical care, compared to only 1.9%
of those without AKI. The mortality of the 12 patients ad-
mitted to critical care was considerably higher (23.1%) than
the overall hospital mortality, which for the total emergency
admissions population was 5.4%. Of the critical care survi-
vors, 10.0% (1 patient) remained dialysis dependent. Patients
who developed AKI in hospital were less likely to require
critical care (5.7%) than those developing AKI pre admission
(6.6%), however this was not significant (odds 0.9, p = 0.86).
The hospital mortality for the AKI group was 7.8% (3.8
to 13.8) compared to only 4.3% (2.0 to 8.0) of the admis-
sions who did not have AKI. The odds of death in the AKI
group compared to those without AKI was 1.9, which was
non-significant (p = 0.193), (95% C.I. odds 0.72-4.90). The
hospital mortality is similar for pre admission AKI (8.6%),
or post admission AKI (7.4%).
Whilst there is noticeable overlap, there is a definite
increase in mortality with increasing severity of AKI. Patients
with stage 1 AKI (Rifle risk) have an odds ratio of death of
0.9 (0.2 to 3.2, midp.exact p = 0.917), stage 2 (RIFLE-I equiva-
lent) an odds ratio of 3.0, (0.8 to 10.0, p = 0.107) and increas-
ing to 3.6 (0.5 to 16.4, p = 0.183) for stage 3 (RIFLE-F).
Discussion
Our study demonstrates that AKI occurs in almost a quar-
ter of emergency admissions in a large single centre univer-
sity teaching hospital. This is even higher (38.1%) in the
subgroup of patients where true baseline renal function
was known at the time of admission. However the inci-
dence of AKI varies depending on which scoring system
was used. The differences between the less severe stages
when using RIFLE or AKIN are small, and this is consistent
with what has been seen in previous validation studies for
both systems. The time criteria used in the definition for
each system, with RIFLE using a change in serumcreatinine or eGFR over 7 days as opposed to 48 hours is
the most likely explanation for this.
The AKIB system, which does not include urine output,
gives a lower incidence of total AKI at 20.8%. This suggests
that urine output may be more sensitive than serum creatin-
ine as an early indicator of renal dysfunction (although
probably much more difficult to assess accurately).
Whilst the overall incidence of AKI is higher at 38.1% in
the group when baseline renal function was known com-
pared to 25.4% in the whole group the breakdown across
RIFLE or AKI stages 1/2/3 was almost identical. RIFLE R
60.5% (whole cohort) 61.3% (known baseline cohort), RIFLE
I 27.9% (whole cohort) 26.9% (known baseline cohort),
RIFLE F 11.6% (whole cohort) 11.8% (known baseline
cohort). This is consistent with what has been seen in the
Zeng US study with a split of AKI 1 70.9%, AKI 2 17.2%,
AKI 3 12.0%.
Irrespective of the definition used, in both the total
cohort and sub group analysis, we have shown AKI has a
significant impact on length of hospital stay, use of critical
care beds and mortality, even at the lower end of the sever-
ity of injury, which has also been seen in large studies in
Italy and the US [8,20]. In our study AKI is associated with
increased length of hospital stay, increased likelihood of
admission to critical care (odds = 5.2, 2.3 to 12.7), and
increased risk of death (odds = 3.7, 1.9 to 7.3). The presence
of AKI and its severity correlated positively with both
length of stay and hospital mortality. Median length of stay
in the total cohort more than doubles from 4.0 days with-
out AKI, up to 10.0 days with AKI (subgroup 5.0 days with-
out AKI, up to 9.0 days with AKI). Although the more
severe AKI episodes were small in number, so limiting the
statistical power, the odds ratio of death increases from 2.0
with stage 1 to 9.0 for stage 3 (RIFLE-F). The figures in our
study are comparable to other studies which have shown
odds ratio of 2.0 for death in stage 1 and 10.1 in stage 3 [8].
Previous reports demonstrate that patients receiving
RRT make up a small proportion of those reaching
RIFLE-F in an ICU, yet the hospital mortality rate is
greater than five times higher than that of the same ICU
population without AKI [20,31-33]. In our study we also
find that hospital mortality in critical care patients is
nearly five times higher in patients with AKI (of any stage)
compared with those patients that do not develop an AKI
(8.1 vs 1.7% respectively). In the past this has been attrib-
uted to AKI simply being an indicator of illness severity,
but this is now being challenged [34]. The increased
morbidity and mortality seen with increasing severity of
AKI is associated with an increased risk of “non-renal”
complications such as bleeding and sepsis, but AKI may
also influence remote organ function [35]. In the total
cohort and subgroup, approximately one third of patients
reaching RIFLE F required RRT. This has significant cost
and resource implications, and if chronic dialysis patients’
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admissions.
Although the weeks studied were not consecutive we
found no statistical differences between the patients in
each week, and the variation in admission profile in the
overall number of admissions, demographics, gender,
age which could have affected the incidence of AKI were
not different. Although the study was conducted in a
single academic centre, only 9% of the admitted patients
were under tertiary specialties and only 7% of patients
were already known to the renal services, we feel our
data is generally applicable to all but the smallest
secondary care centres. Although the study is not as nu-
merically large as some others, its major strength is that
all admissions were captured and each case scrutinised
by a nephrologist making it unlikely that any cases were
missed, as can occur when relying only on electronic
records as other larger studies have done [8,20,32]. Fur-
thermore our study population included very few pa-
tients (4.3%) who did not have any serum creatinine
values compared to nearly 24% in Zeng’s study [8].
A limitation which affects most studies in AKI, includ-
ing ours, is the absence of a baseline creatinine for many
patients hindering accurate assessment of baseline renal
function. In our study 45% of patients had a known
baseline, and so an estimated baseline was required in
the remainder. In these cases we assumed a baseline
eGFR of 75 mls/min per 1.73 m [2] as recommended by
the Acute Dialysis Quality Initiative, and used a serum
creatinine of 60 umol/L for females and 80 umol/L for
males (as the midpoint of our laboratory normal range).
Recently published data from Siew et al. suggests that
using many multiple imputation methods to calculate
baseline function improve AKI misclassification but this
has yet to be commonly accepted [36]. Other authors
have encountered similar difficulties so that Hoste et al.
used a ‘back calculated creatinine’ via MDRD using an
assumed eGFR of 75 mls/min in approximately 50% of
their cohort and Zeng et al. used an estimated baseline
in 24.6% of their cohort. Back calculation via eGFR has
its own problems since it is well recognised that esti-
mated GFR is wildly inaccurate when serum creatinine
is normal or near normal (+30% from true GFR), and
serum creatinine needs to have been stable for at least
4 days before it approximates to true GFR.
Using RIFLE our AKI incidence of 23.6% is higher
than that previously reported. The recent study by Zeng
et al., demonstrated an incidence of 16.1% (using RIFLE)
and Uchino 18.0%, both studies using a cohort including
all hospitalisations. Our sub group analysis using the
population with a known baseline suggested an even
higher incidence, between 32.4 – 35.4% depending on
the AKI definition used. Interestingly, the Zeng study
also found an increased incidence when analysing onlythe sub-group with a known baseline creatinine value.
Their variation from 18 to 33% depending on the defin-
ition of AKI used, and also depending on how estima-
tion of unknown baseline renal function was calculated,
gives an incidence comparable to our results, and higher
than previous studies. The higher overall incidence of
AKI at 67.4% in the Hoste study most likely reflects that
it was studying a very different group of patients using
an ICU population only [32].
The potential risk factors assessed in the study are all
commonly found co-morbidities in any hospital popula-
tion. The significant effects of age, sepsis, diuretic use
and pre-existing CKD highlight the importance of these
factors in the development of AKI - aspects which may
be under-recognized by clinicians. Educating clinicians
to identify ‘at risk’ patients, both at the time of admis-
sion and also prior to this, will become increasingly
important as we deal with an ageing population and its
associated increased incidence of CKD. ‘Classical’ risk
factors for AKI such as angiotensin blockade and radio-
contrast use seem to play a smaller role than anticipated
as risk factors for development of AKI in this and other
studies. This may be due to already increased awareness of
these modifiable factors. NSAIDs were not shown to be a
significant risk factor despite being a well-recognised risk
factor. The increased awareness of their association with
renal dysfunction in an acute and chronic setting means
has reduced their use in the elderly, CKD and heart failure
patients – all groups which are at higher risk of AKI.
In summary, this study demonstrates that AKI is very
common in acute unselected hospital admissions. Risk
factors present at the time of admission suggest that it
may be predictable, and therefore in some cases avoid-
able. If so, we calculate that a modest reduction of 10%
in the incidence of AKI could save around 3,000 bed
days per annum in similarly sized acute hospitals
with 900–1000 beds. Whilst this has significant finan-
cial implications, of even greater importance is the
benefit to the individual patient in terms of reduced
morbidity, length of stay, long term renal outcome,
and in some cases likelihood of death. To achieve such
a reduction in the incidence of AKI would require a
reliable method of early identification of the ‘at risk’
patient, and in particular those in whom AKI may be
avoidable.
Conclusion
AKI in acute unselected admissions to a large acute
hospital is common, affecting around 25% of patients. In
many cases this is relatively mild and may resolve spon-
taneously, however it is associated with increased length
of hospital stay, increased likelihood of admission to
critical care, and increased risk of death. Despite the
publication of the NCEPOD report into AKI, routine
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ately may still be being overlooked. Risk factors for AKI
can be identified and may be of use in alerting clinicians
to ‘at risk’ patients who could then be monitored more
closely. If targeted effective interventions can be devel-
oped it seems likely that substantial clinical benefits for
the patient, as well as financial and structural benefits
for the healthcare organisation may accrue.
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